Table 2.
Exercise | Non‐exercise | |||||
---|---|---|---|---|---|---|
Pre | Post | Change,% | Pre | Post | Change,% | |
MuRF1 (AU) | 1.48 ± 1.33 | 2.28 ± 2.34a | 63.68 ± 91.50& | 2.27 ± 1.72 | 2.19 ± 2.51 | −1.69 ± 69.48 |
Atrogin‐1 (AU) | 1.01 ± 0.74 | 0.87 ± 0.43 | −1.04 ± 30.90 | 1.21 ± 0.76 | 1.08 ± 0.62 | −0.78 ± 29.79 |
Beclin1 (AU) | −2.25 ± 2.51 | −1.98 ± 3.18 | −4.09 ± 92.33 | 0.44 ± 2.52 | −0.40 ± 2.51 | ‐27.74 ± 78.73 |
LC3B (AU) | 38.95 ± 56.31 | 33.87 ± 39.07 | 8.15 ± 41.02 | 37.67 ± 31.58 | 30.32 ± 22.77 | 10.41 ± 34.76 |
Endothelin‐1 (pg/mL) | 1.20 ± 0.73 | 1.26 ± 1.16 | 0.99 ± 0.43 | 0.93 ± 0.37 | ||
Citrate synthase activity (μmol/min/μg protein) | 28.25 ± 13.15 | 30.81 ± 8.42 | 30.71 ± 10.67 | 31.15 ± 3.96 |
Data are mean ± SD.
Significantly different from baseline.
Trending toward significantly different from baseline (P = 0.08). &trending toward significantly different from NON (P = 0.11).